1. Introduction {#sec1-ijms-17-01239}
===============

Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disease that affects one out of 500 individuals from the general population \[[@B1-ijms-17-01239]\]. It is a clinically variable and genetically heterogeneous disease. In fact, more than 20 genes were related with HCM and a total number of about 1400 distinct mutations were identified in affected patients \[[@B2-ijms-17-01239]\]. The most frequently encountered mutations fall within myosin heavy chain 7 (*MYH7*) and myosin binding protein C (*MBPC3*) \[[@B3-ijms-17-01239],[@B4-ijms-17-01239]\]. Sequencing of sarcomere protein genes in patients fulfilling clinical diagnostic criteria identifies a disease-causing mutation in only 35% to 60% of cases \[[@B5-ijms-17-01239],[@B6-ijms-17-01239],[@B7-ijms-17-01239],[@B8-ijms-17-01239]\]. Identification of an HCM-causing mutation is an important step in the disease's clinical management, not only to better support the clinical diagnosis in the proband but also to either exclude or confirm the presence of disease-causing mutations in other family members.

Considering the extreme genetic heterogeneity of the disease and the cost of genetic testing, several attempts were made to identify the clinical predictors of an underlying mutation \[[@B9-ijms-17-01239],[@B10-ijms-17-01239],[@B11-ijms-17-01239]\]. In a large study of HCM patients genotyped for mutations in nine genes, the presence of a set of five clinical markers, including age at diagnosis \<45 years, accounted for an 80% likelihood of positive genetic testing \[[@B11-ijms-17-01239]\].

In addition, more reliable, precise, and possibly not time-consuming molecular diagnostic approaches are needed. In this regard, Next-Generation Sequencing (NGS), which has already been applied for the diagnosis of hereditary cardiovascular conditions as well as of other diseases \[[@B12-ijms-17-01239],[@B13-ijms-17-01239],[@B14-ijms-17-01239],[@B15-ijms-17-01239],[@B16-ijms-17-01239]\], may represent a suitable tool. Targeted gene panels were shown to generate results with analytical quality identical to Sanger sequencing, and to have the advantage of being faster and cheaper with better coverage and sensitivity than that used in more expanded analyses.

The purpose of the present study was to analyse the yield of NGS applied to the genetic screening of a well-phenotyped Italian HCM cohort, composed of patients with both early- and late-onset diagnosis, also including patients with positive family history, and to explore the ability of NGS to accomplish the molecular diagnostic needs in clinical practice.

2. Results {#sec2-ijms-17-01239}
==========

2.1. Description of Study Population {#sec2dot1-ijms-17-01239}
------------------------------------

The clinical characteristics of patients enrolled in the study are shown in [Table 1](#ijms-17-01239-t001){ref-type="table"}A.

The patients were divided into two subgroups of 35 patients each, depending on the age at HCM diagnosis: the early-onset (EO) group with a mean age at diagnosis of 18.6 ± 8.5 years and the late-onset (LO) group with a mean age at diagnosis of 70.4 ± 4.8 years. The number of patients with a positive family history for HCM was significantly higher in the EO group (*p* = 0.0001) ([Table 1](#ijms-17-01239-t001){ref-type="table"}B). Thirty-four patients were women and 36 were men. The sex distribution of patients was different in the two subgroups, with more males in the EO group (*p* = 0.0001). The left atrium size was significantly different in the two groups (*p* = 0.0001), with LO patients more frequently exhibiting left atrial enlargement. The obstructive form of HCM was less frequently observed in the EO as compared to the LO group (*p* = 0.03). Evolution of the disease towards end stage (left ventricular ejection fraction \<50%) was observed only in the EO group. None of the other clinical features considered in the study was significantly different between the two groups.

2.2. Sequencing {#sec2dot2-ijms-17-01239}
---------------

The coding region of each of the 17 HCM phenotype causative genes included in the HCM panel was sequenced on Personal Genome Machine (PGM) IonTorrent sequencer. The 17 genes included in the HCM panel used for this analysis are shown in [Table 2](#ijms-17-01239-t002){ref-type="table"}. Sequencing produced an average of 240,000 reads per patients; the mean read length was 130 bp; the average read depth per sample was 620× with a mean percentage of reads on target of 93.77%; the mean percentage of regions of interest (ROI) covered at least by 20× was 98.6%, and that covered at least by 100× was 94.7%. Details of the sequencing metrics for each patient are reported in [Table 3](#ijms-17-01239-t003){ref-type="table"}.

Two hundred eighty-two variants were identified within the 17 genes analysed: two were ins/del, 175 were intronic, 37 missense, 59 synonimous, five splicing, and four stop mutations. After filtration, 41 variants with a possible clinical effect were selected and confirmed by Sanger sequencing (data not shown). These variants were located in nine of the 17 genes: *MYBPC3* (17/41 = 41%); *MYH7* (10/41 = 24%); troponin T2 (*TNNT2*), caveolin 3 (*CAV3*), and myosin heavy chain 6 (*MYH6*) (3/41 = 7.5% each); troponin I 3 (*TNNI3*) (2/41 = 4.8%); and galactosidase alpha (*GLA*), myosin light chain 2 (*MYL2*), and myosin light chain 3 (*MYL3*) (1/41 = 2.5% each). Thirty-four were known variants, whereas seven were novel. Out of the seven new missense mutations, four had uncertain significance, two were likely pathogenic, and one was likely benign. Considering the 34 known variants, 15 were known to have pathogenic effect, six were likely pathogenic, one was likely benign, and 12 were known registered variants but with unknown clinical significance ([Table 4](#ijms-17-01239-t004){ref-type="table"}). Mutations in sarcomeric genes accounted for 90% of all identified mutations, with *MYBPC3* and *MYH7* alone accounting for 65% of all mutations. Considering only mutations in *MYBPC3*, eight missense mutations and nine truncating mutations were identified ([Table 4](#ijms-17-01239-t004){ref-type="table"}).

2.3. Group Comparison after Sequencing {#sec2dot3-ijms-17-01239}
--------------------------------------

The mutation detection rate was 85.7% (30/35) in the EO group and 22.9% (8/35) in the LO group.

The number of patients in which the molecular screening allowed the identification of at least one mutation was significantly different in the two groups of patients with different age at diagnosis (*p* \< 0.0001). The overall detection rate, regardless of the age of onset, was 54.3% (38/70). The NGS analysis confirmed the known mutational status of the 22 controls (seven positive and 15 negative) included in this study. Mutations identified in each patient are listed in [Table 5](#ijms-17-01239-t005){ref-type="table"}. Considering only patients with positive family history, the detection rate was 88% (22/25), ranging from 75% (3/4) in the LO group to 90.5% (19/21) in the EO group. Considering sporadic cases only, the overall detection rate was 35.5%, with a significant difference between EO (11/14, 78.6%) and LO (5/31, 16%), *p* \< 0.0002.

In the EO group, patients EO13 and EO33 carried three different mutations in *MYBPC3*. One of them was clinically characterized by an unfavourable course with evolution to end stage disease.

Four patients carried two different mutations: EO23 carried two mutations in *MYH7*, whereas EO6, EO11, and EO21 carried two mutations in two different genes ([Table 5](#ijms-17-01239-t005){ref-type="table"}). In the LO group, only two patients, LO8 and LO17, harboured two mutations in different genes ([Table 5](#ijms-17-01239-t005){ref-type="table"}).

The distribution of the identified gene mutations was similar between the two groups with the exceptions of *MYH6* and *TNNT2*. In fact, mutations in *MYH6* were identified in the LO group only, whereas mutations in *TNNT2* were identified in the EO group only.

3. Discussion {#sec3-ijms-17-01239}
=============

This report describes the results of a genetic screening obtained through NGS approach in an Italian population of unrelated and clinically well characterized HCM cases, divided into two groups according to age at diagnosis. Our population included a good percentage of patients with a family history of HCM. As expected, the prevalence of familial forms was higher in the EO group, whereas the prevalence of sporadic forms was higher in the LO group.

The key finding of our investigation was the higher yield of mutation detection rate in the EO group and in patients with a family history of disease, with 90.5% of cases carrying an identified mutation. The overall yield of genetic testing was close to 50%, and, as previously reported in the literature \[[@B4-ijms-17-01239],[@B7-ijms-17-01239],[@B8-ijms-17-01239],[@B9-ijms-17-01239],[@B11-ijms-17-01239]\], mutations in *MYBPC3* and *MYH7* accounted for about 65% of all variants. Other mutations were found in six additional sarcomeric genes (*TNNT2*, *CAV3*, *MYH6*, *TNNI3*, *MYL2*, and *MYL3*) and in one non-sarcomeric gene (*GLA*). Approximately a quarter of all variants were novel, most of them belonging to *MYH7*. The pathogenicity of novel mutations was verified through appropriate software for analysis.

HCM is a disease characterized by a relevant heterogeneity of both morphological and clinical features. For this reason, despite the growing knowledge on its genetic basis, the establishment of a more precise genotype--phenotype correlation has been difficult to achieve.

The main original aspect of our investigation was to test through NGS a wide range of HCM-causing genes (14 sarcomeric and three non-sarcomeric) while comparing the extreme ages of disease onset and evaluating the impact of familial occurrence of the disease even in patients with late diagnosis. Due to the small sample size of the population, our study could not address the issue of a relationship between genetic variants and phenotypic characteristics of different HCM onset patients. Notably, the presence of double and triple mutations was detected mostly among younger patients, and one of them showed a more severe form of the disease.

The different rate of pathogenic mutations found in HCM patients with early and late onset of the disease was consistent with the literature \[[@B17-ijms-17-01239],[@B18-ijms-17-01239],[@B19-ijms-17-01239]\], confirming that some mutations can be found mainly in young HCM patients (*TNNT2*) whereas other mutations are detected exclusively in the elderly (*MYH6*) \[[@B17-ijms-17-01239],[@B18-ijms-17-01239],[@B19-ijms-17-01239]\].

In our study, a majority of patients with young age at diagnosis had a positive genetic testing (80% of cases), four-fold higher than that of the elderly and sporadic HCM cases. These data, together with previous observations, reinforce the concept that age at HCM diagnosis is a powerful predictor of positive genetic testing \[[@B11-ijms-17-01239],[@B17-ijms-17-01239],[@B18-ijms-17-01239],[@B19-ijms-17-01239]\]. We also support the notion that family history of HCM has a key role in appropriately addressing the genetic test. In fact, among HCM patients with a late diagnosis, those with a family history of the disease had a higher rate of mutation detection (75%).

We used an expanded panel of 17 genes in the attempt to improve the mutation detection rate. With this approach we mostly confirmed the type of mutations and the mutation distribution already described in the literature for HCM. In particular, the most frequent sarcomeric gene mutations, namely those in *MYBPC3* and *MYH7*, accounted for the majority of the positive findings. Moreover, six of the seven novel mutations identified in our patients were in the main sarcomeric genes (three in *MYH7*, one in *MYH6*, one in *MYBPC3*, and one in *TNNI3*). In this regard, the limitations of using a wide diagnostic panel for HCM genetic testing have been recently highlighted in one of the largest clinical genetic studies ever reported for HCM \[[@B20-ijms-17-01239]\]. Consistently, a panel designed only for the main HCM genes (*n* = 9), was able to successfully screen a large cohort of HCM patients \[[@B21-ijms-17-01239]\]. Our findings support the choice of a limited, well-selected panel of HCM genes as the best tool for diagnostic purposes.

4. Materials and Methods {#sec4-ijms-17-01239}
========================

4.1. Patient Selection {#sec4dot1-ijms-17-01239}
----------------------

Seventy patients with clinical diagnosis of HCM were included in the study. We selected 35 patients with early diagnosis of the disease (≤25 years, EO-early onset) and 35 patients with a late diagnosis (≥65 years, LO-late onset). All patients underwent a cardiologic evaluation as well as genetic counselling. Clinical data for each patient included a detailed personal and family history and a thorough scrutiny of the age at which HCM was first diagnosed. Both electrocardiographic and echocardiographic examinations were performed at the time of inclusion into the study. The echocardiographic parameters included both structural measurements and resting LV outflow tract gradients derived from the continuous-wave Doppler velocities. The clinical diagnosis of HCM was based on the echocardiographic demonstration of a hypertrophied and not dilated left ventricle (wall thickness \>15 mm in adults, or the equivalent wall thickness relative to body surface area in children) in the absence of another cardiac or systemic disease that could produce comparable left ventricular hypertrophy \[[@B22-ijms-17-01239],[@B23-ijms-17-01239]\].

The mutational status for *MYH7*, *MYBPC3*, *TNNI3*, *TNNT2*, *TPM1*, and *MYL2* genes was already known in 22/70 patients (8 EO and 14 LO patients). All coding exons (±20 bp) of the six genes were previously analysed by Sanger sequencing. The 22 samples were included in our study as positive and negative controls for the six genes also present in our NGS panel. The seven positive controls carried mutations in *MYBPC3* (EO7, EO29, EO33, EO35), *MYH7* (LO13), *TNNI3* (EO30), and *MYL2* (EO20). The 15 negative controls for the six genes were: EO10, EO15, LO5, LO6, LO9, LO12, LO19, LO21, LO22, LO25, LO27, LO28, LO29, LO32, and LO33.

This study was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards (The approval identification number: 42 of 28 September 2007). A signed informed consent for blood sampling was obtained from all patients included in the study.

4.2. DNA Extraction and Quantification {#sec4dot2-ijms-17-01239}
--------------------------------------

Genomic DNA was extracted from peripheral whole blood using a commercially available kit (Invitrogen, Milan, Italy), and then quantified using Qubitds DNA HS Assay Kit on Qubit 2.0 Fluorometer (Invitrogen).

4.3. Sequencing {#sec4dot3-ijms-17-01239}
---------------

Seventeen genes known to be causative of HCM phenotype were selected for targeted sequencing ([Table 2](#ijms-17-01239-t002){ref-type="table"}). A custom panel for coding DNA (+/−25 bp of intronic flanking regions) analysis of selected genes was designed online using Ion AmpliSeq Designer 2.0.3 (<https://www.ampliseq.com/browse.action>) \[[@B24-ijms-17-01239]\]. The final custom panel was composed of 358 amplicons divided into two primer pools for a total of 61.89 kb of DNA. The panel covered 96.47% of regions of interest (ROI). Libraries were prepared using Ion AmpliSeq Library Kit v2.0 (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. One of 16 barcodes of the Ion Xpress Barcode Adapters1-16 Kit (Thermo Fisher Scientific Life Sciences Solutions, Carlsbad, CA, USA) was added to each sample. Libraries were quantified with Qubit dsDNA HS Assay Kit on Qubit 2.0 Fluorometer (Molecular Probes, Eugene, OR, USA) and equimolar amounts of each library were used to prepare template for clonal amplification. Emulsion PCR with Ion PGM Template OT2 200 Kit (Life Technologies, Carlsbad, CA, USA) was performed on OneTouch2 Systems (Life Technologies, Carlsbad, CA, USA). Templates were enriched using Ion OneTouch ES (Life Technologies, Carlsbad, CA, USA) and prepared for 316v2 chip loading (Life Technologies, Carlsbad, CA, USA). Groups from 12 to 16 sample libraries were sequenced on each chip. Sequencing runs were performed on Ion Torrent Personal Genome Machine (PGM, Life Technologies) using Ion PGM Sequencing 200 Kit v2, according to the manufacturer's instructions.

4.4. Alignment {#sec4dot4-ijms-17-01239}
--------------

Data analysis was performed using the Torrent Suite Software v.4.0.2. (Life Technologies, Carlsbad, CA, USA). Reads were aligned to human reference genome hg19 from UCSC Genome Browser \[[@B25-ijms-17-01239]\] and to a designed bed file from Ion AmpliSeq Designer results. Alignments were visually verified with Integrative Genomics Viewer IGV v.2.3, Broad Institute \[[@B26-ijms-17-01239]\].

4.5. Coverage Analysis {#sec4dot5-ijms-17-01239}
----------------------

The average read depth and the percentage of reads that mapped on ROI out of the total number of reads (reads on target) was calculated using Coverage Analysis plug-in (Life Technologies, Carlsbad, CA, USA). For each sample the percentage of ROI covered by at least 100× and 20× using amplicon coverage matrix file was calculated.

4.6. Variant Analysis {#sec4dot6-ijms-17-01239}
---------------------

Variant calling was performed with Variant Caller plug-in configured with germ line-low stringency parameters. Variants were annotated using Ion Reporter 4.0 software (Carlsbad, CA, USA) \[[@B27-ijms-17-01239]\]. Common single nucleotide variants (minor allele frequency MAF\>5%, source 1000 Genomes), exonic synonymous variants, and intronic variants were removed from the analysis, while exonic non-synonymous, splice-site, and loss-of-function variants were analysed. The novel variants were analysed by means of three types of prediction software (SIFT, POLYPHEN, and PROVEAN) and classified based on the concordance of the prediction between the three types: "likely pathogenic," "likely benign" (3/3 concordance), or "uncertain significance" (2/3 concordance).

4.7. Variant Validation {#sec4dot7-ijms-17-01239}
-----------------------

The identified variants were validated by Sanger sequencing using standard protocols. Specific primers were designed for the analysis. Polymerase Chain Reaction (PCR) products were directly sequenced by using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies Corporation, Carlsbad, CA, USA). Sample analysis was performed on an ABI PRISM 3130xl Genetic Analyser (Applied Biosystems, Carlsbad, CA, USA).

4.8. Statistical Analysis {#sec4dot8-ijms-17-01239}
-------------------------

Statistical analysis was performed with SPSS statistical software (SPSS Inc., Chicago, IL, USA, version 17.0). Continuous variables are expressed as mean±SD. Comparisons between the two groups were performed using a Student's *t*-test. The association between the mutational status and the clinical features of the two patient groups was evaluated using Chi-square and Fisher's exact tests. A *p* value was considered statistically significant when \<0.05.

5. Conclusions {#sec5-ijms-17-01239}
==============

In summary, through NGS, we were able to detect pathogenic mutations responsible for HCM, particularly in patients with early onset of the disease and in those with a family history of HCM. Our findings document the suitability of a novel molecular diagnostic strategy for clinical purposes and the important role of appropriate patient selection in making genetic molecular testing more cost-effective.
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###### 

(**A**) Clinical characteristics of HCM patients with early or late onset of disease; (**B**) Familial vs. sporadic HCM.

ijms-17-01239-t001a_Table 1

###### 

(**A**)

  Variables                               Early-Onset *n* = 36   Late-Onset *n* = 35   *p*
  --------------------------------------- ---------------------- --------------------- --------
  Age at diagnosis (years)                18.6 ± 8.5             70.4 ± 4.8            0.0001
  Male                                    27 (77.1)              9 (25.7)              0.0001
  LV obstruction                          14 (40)                24 (68.6)             0.03
  Family history of HCM                   21 (60)                4 (11.4)              0.0001
  NYHA functional class                                                                
  I                                       24 (68.6)              4 (11.4)              0.0001
  II                                      9 (25.7)               25 (71.4)             
  III                                     2 (5.7)                6 (17.1)              
  Unexplained syncope                     5 (14.3)               6 (17.1)              1
  Non sustained ventricular tachycardia   6 (24)                 5 (22.7)              1
  Left atrial dimension (mm)              39.3 ± 6.2             45 ± 4.5              0.0001
  Maximal LV wall thickness (mm)          21.4 ± 6.2             18.7 ± 2.6            0.02
  Late gadolinium enhancement             24/29 (82.8)           9/19 (47.4)           0.01
  Atrial fibrillation                     11 (31.4)              10 (28.6)             1
  End stage disease                       4 (11.4)               0 (0)                 0.11
  Myectomy                                2 (5.7)                0 (0)                 0.49
  ICD implantation                        12 (34.3)              2 (5.7)               0.006
  Death                                   0 (0)                  1 (2.9)               1

ijms-17-01239-t001b_Table 1

###### 

(**B**)

  Patients       All *n* = 70   EO *n* = 35   LO *n* = 35   *p*
  -------------- -------------- ------------- ------------- --------
  Familial HCM   25 (36)        21 (60)       4 (14.4)      0.0001
  Sporadic HCM   45 (64)        14 (40)       31 (88.6)     0.0001

In (**A**): Continuous variables are expressed as mean ± SD. Qualitative variable are expressed as *n* (%). HCM: hypertrophic cardiomyopathy; NYHA: New York Functional Class; LV: left ventricular; ICD: implantable cardioverter defibrillator; In (**B**): Variable are expressed as *n* (%); EO: early-onset; LO: late-onset.

ijms-17-01239-t002_Table 2

###### 

Metrics of the 17 genes included into the HCM panel.

  \#No.   Gene Name   Ref Seq NCBI   Genomic Location (hg19)     Description                                                   Amplicons   Coverage (%)   Target (bp)   Missed (bp)
  ------- ----------- -------------- --------------------------- ------------------------------------------------------------- ----------- -------------- ------------- -------------
  1       *MYBPC3*    NM_000256      chr11:47352958-47374253     myosin binding protein C, cardiac                             53          100            5458          105
  2       *MYH7*      NM_000257      chr14:23881948-23904870     myosin, heavy chain 7, cardiac muscle, β                      67          98             7746          231
  3       *TPM1*      NM_001018005   chr15:63334838-63364111     tropomyosin 1 α chain isoform 7                               23          99.91          2245          2
  4       *TNNT2*     NM_001001430   chr1:201328143-201346805    troponin T type 2, cardiac isoform 1                          20          100            2357          0
  5       *TNNI3*     NM_000363      chr19:55663137-55669100     troponin I, cardiac                                           10          99.9           989           1
  6       *MYL2*      NM_000432      chr12:111348626-111358404   slow cardiac myosin regulatory light chain 2                  9           84.8           858           46
  7       *MYL3*      NM_000258      chr3:46899357-46904973      slow skeletal ventricular myosin alkali light                 9           94,6           894           136
  8       *ACTC1*     NM_005159      chr15:35080297-35087927     cardiac muscle α actin 1 proprotein                           13          100            1440          0
  9       *LAMP2*     NM_002294      chrX:119560004-119603204    lysosomal-associated membrane protein 2 isoform               21          100            2077          0
  10      *PRKAG2*    NM_016203      chr7:151253203-151574316    AMP-activated protein kinase γ 2 subunit                      26          84.3           2713          426
  11      *GLA*       NM_000169      chrX:100652779-100663001    α-galactosidase A precursor                                   14          100            1647          0
  12      *MYH6*      NM_002471      chr14:23851199-23877482     myosin heavy chain 6                                          66          94.52          7707          422
  13      *TNNC1*     NM_003280      chr3:52485108-52488057      troponin C, slow                                              8           98.2           792           14
  14      *CSRP3*     NM_003476      chr11:19203578-19223589     cysteine and glycine-rich protein 3                           8           100            840           0
  15      *PLN*       NM_002667      chr6:118869442-118881586    phospholamban                                                 2           100            210           0
  16      *TCAP*      NM_003673      chr17:37821599-37822806     telethonin                                                    5           100            606           0
  17      *CAV3*      NM_033337      chr3:8775486-8788451        Homo sapiens caveolin 3 (CAV3), transcript variant 1, mRNA.   4           100            558           0

Gene symbols: *TPM1*: tropomyosin 1; *ACTC1*: actin, α, cardiac muscle 1; *LAMP2*: lysosomal associated membrane protein 2; *PRKAG2*: protein kinase AMP-activated non-catalytic subunit γ 2; *TNNC1*: troponin C 1; *CSRP3*: cystein and glycine-rich protein 3; *PLN*: phospholamban; *TCAP*: telethonin.

ijms-17-01239-t003_Table 3

###### 

Patient sequencing metrics.

  Patients   Mapped Reads   Reads on Target (%)   Uniformity (%)   ROI MEAN COVERAGE   ROI ≥ 20× (%)   *n* of Amplicons \< 20×   ROI ≥ 100× (%)   *n* of Amplicons \< 100×
  ---------- -------------- --------------------- ---------------- ------------------- --------------- ------------------------- ---------------- --------------------------
  EO1        178,727        92.13                 93.95            459.94              98.60           5                         94.97            18
  EO2        178,731        90.57                 94.83            452.19              98.88           4                         95.53            16
  EO3        72,440         91.78                 93.75            185.71              96.93           11                        83.52            59
  EO4        247,711        90.70                 93.90            627.61              99.44           2                         96.09            14
  EO5        111,232        91.03                 93.57            282.82              97.21           10                        91.62            30
  EO6        280,419        93.08                 94.15            729.08              99.16           3                         96.09            14
  EO7        623,594        92.53                 93.81            1611.77             99.44           2                         98.32            6
  EO8        561,715        97.46                 92.18            1529.12             99.44           2                         97.49            9
  EO9        77,846         93.36                 93.83            203.00              96.93           11                        86.87            47
  EO10       381,796        96.33                 93.71            1027.32             99.44           2                         97.21            10
  EO11       311,658        93.28                 93.70            812.08              99.44           2                         96.09            14
  EO12       239,783        93.00                 94.15            622.93              98.88           4                         95.53            16
  EO13       276,453        93.48                 94.44            721.90              99.44           2                         96.09            14
  EO14       215,672        93.30                 94.53            562.09              99.44           2                         95.81            15
  EO15       465,323        94.73                 93.01            1231.34             99.44           2                         96.65            12
  EO16       465,619        97.25                 92.65            1264.84             99.44           2                         96.93            11
  EO17       441,220        95.42                 92.96            1176.05             99.72           1                         97.49            9
  EO18       192,373        98.07                 91.50            526.97              98.60           5                         94.13            21
  EO19       313,968        95.80                 93.72            840.19              99.16           3                         96.65            12
  EO20       192,211        95.35                 94.02            517.24              98.60           5                         95.81            15
  EO21       196,251        95.05                 94.02            521.07              98.88           4                         95.81            15
  EO22       303,435        96.01                 93.55            813.79              98.88           4                         96.65            12
  EO23       322,467        94.14                 92.17            847.94              98.88           4                         95.81            15
  EO24       253,552        95.97                 91.35            679.71              98.88           4                         95.53            16
  EO25       188,696        95.33                 93.96            502.45              98.60           5                         95.53            16
  EO26       182,956        94.99                 92.88            485.47              98.88           4                         94.13            21
  EO27       191,880        94.62                 93.58            507.12              98.88           4                         94.97            18
  EO28       228,313        92.89                 93.22            592.43              98.88           4                         94.69            19
  EO29       199,442        98.07                 92.15            546.33              98.32           6                         94.97            18
  EO30       190,915        97.24                 92.66            518.58              98.04           7                         94.69            19
  EO31       161,793        95.49                 92.19            431.54              97.77           8                         93.30            24
  EO32       245,414        89.57                 93.45            613.99              98.32           6                         95.81            15
  EO33       205,079        95.46                 85.54            546.83              96.65           12                        89.39            38
  EO34       210,900        97.24                 93.66            572.83              98.60           5                         95.25            17
  EO35       147,306        97.24                 92.62            402.14              98.32           6                         94.13            21
  LO1        178,290        90.77                 93.68            321.94              97.77           8                         91.90            29
  LO2        205,008        93.84                 93.97            537.36              99.16           3                         96.09            14
  LO3        159,828        93.15                 93.80            502.12              98.88           4                         95.53            16
  LO4        193,973        93.90                 94.09            1062.97             99.44           2                         96.37            13
  LO5        191,160        93.72                 93.21            1097.36             99.16           3                         96.65            12
  LO6        177,316        94.10                 93.42            931.78              99.44           2                         96.37            13
  LO7        238,812        94.23                 93.77            593.70              97.77           8                         92.18            28
  LO8        158,483        93.67                 93.01            708.10              99.44           2                         97.49            9
  LO9        213,370        93.89                 94.34            861.05              99.44           2                         97.21            10
  LO10       190,285        94.47                 93.70            415.86              98.32           6                         94.41            20
  LO11       182,160        93.99                 94.02            505.35              98.32           6                         94.97            18
  LO12       213,052        92.51                 94.69            532.23              98.88           4                         94.97            18
  LO13       249,591        93.48                 93.92            304.45              96.93           11                        90.78            33
  LO14       195,422        94.82                 94.22            378.77              98.04           7                         92.74            26
  LO15       201,815        95.14                 93.81            717.45              98.60           5                         95.53            16
  LO16       400,156        98.18                 90.79            500.41              98.60           5                         94.41            20
  LO17       274,868        95.75                 91.07            423.42              98.04           7                         92.74            26
  LO18       158,695        92.07                 94.09            457.87              98.32           6                         94.97            18
  LO19       195,752        89.66                 93.66            206.68              96.65           12                        86.03            50
  LO20       83,846         88.25                 93.28            490.24              98.32           6                         94.13            21
  LO21       179,015        91.57                 94.00            408.12              98.60           5                         94.69            19
  LO22       170,180        89.07                 93.89            735.17              98.60           5                         94.97            18
  LO23       161,290        90.82                 93.26            680.84              99.16           3                         96.09            14
  LO24       281,769        92.16                 93.07            536.34              98.60           5                         95.53            16
  LO25       145,219        93.37                 93.76            517.60              99.16           3                         95.81            15
  LO26       390,025        97.57                 92.65            508.78              98.88           4                         95.53            16
  LO27       124,848        87.30                 93.29            651.69              99.16           3                         95.25            17
  LO28       214,031        89.02                 93.84            550.53              99.16           3                         96.37            13
  LO29       203,428        88.93                 94.12            479.56              98.88           4                         95.53            16
  LO30       127,496        90.40                 93.91            452.05              98.32           6                         94.69            19
  LO31       25,524         95.49                 93.62            409.17              98.04           7                         93.02            25
  LO32       329,472        93.56                 94.58            559.60              99.16           3                         96.09            14
  LO33       265,155        95.60                 93.94            414.68              98.32           6                         94.13            21
  LO34       21,736         97.78                 89.25            628.59              98.88           4                         95.81            15
  LO35       352,805        94.55                 92.69            466.05              97.77           8                         94.69            19
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###### 

Mutations detected per gene.

  Gene ID    Chrom       Position    Exon                 DNA Change     Protein Change      Mutation Type   dbSNP         Prev. Rep.    GMAF               SIFT                      POLYPHEN                  PROVEAN (cutoff = −2.5)        Clinical Significance
  ---------- ----------- ----------- -------------------- -------------- ------------------- --------------- ------------- ------------- ------------------ ------------------------- ------------------------- ------------------------------ ------------------------------
  *CAV3*     chr3        8787313     2                    c.216C\>G      Cys72Trp            MISSENSE        rs116840776   yes           0.00100 (G)        deleterious 0             probably damaging 0.999   deleterious −6.167             known/uncertain significance
  chr3       8787330     2           c.233C\>T            Thr78Met       MISSENSE            rs72546668      yes           0.00200 (T)   tolerated 0.05     possibly damaging 0.537   neutral −0.833            known/uncertain significance   
  chr3       8787497     2           c.400G\>T            Ala134Ser      MISSENSE                                                        deleterious 0.01   benign 0.07               neutral 0.862             new/uncertain significance     
  *GLA*      chrX        100653420   6                    c.937G\>T      Asp313Tyr           MISSENSE        rs28935490    yes           0.0021 (A)         deleterious 0             probably damaging 0.952   deleterious −3.183             known/uncertain significance
  *MYBPC3*   chr11       47371426    5                    c.553A\>T      Lys185Ter           STOP            rs375607980   yes                                                                                                                 known/pathogenic
  chr11      47371414    5           c.565G\>A            Val189Ile      MISSENSE            rs11570052      yes           0.00200 (T)   tolerated 0.44     benign 0.132              Neutral −0.418            known/likely benign            
  chr11      47365154    13          c.1112C\>G           Pro371Arg      MISSENSE            rs397515887     yes           0.00020 (A)   deleterious 0      probably damaging 0.994   deleterious −8.043        known/uncertain significance   
  chr11      47365147    13          c.1120C\>T           Gln374Ter      STOP                rs730880635     yes                                                                                                known/pathogenic               
  chr11      47364429    15          c.1409G\>A           Arg470Gln      MISSENSE                            yes                         deleterious 0.01   probably damaging 0.982   deleterious −3.094        known/uncertain significance   
  chr11      47364270    16          c.1483C\>T           Arg495Trp      MISSENSE            rs397515905     yes                         deleterious 0      probably damaging 0.999   deleterious −5.228        known/uncertain significance   
  chr11      47364162    16          c.1591G\>C           Gly531Arg      MISSENSE            rs397515912     yes           0.00020 (G)   deleterious 0      probably damaging 0.996   deleterious −7.038        known/likely pathogenic        
  chr11      47364129    16          c.1624G\>C           Glu542Gln      MISSENSE/SPLICING   rs121909374     yes           0.00008 (G)                                                                          known/pathogenic               
  chr11      47360071    22          c.2308G\>A           Asp770Asn      MISSENSE/SPLICING   rs36211723      yes                                                                                                known/pathogenic               
  chr11      47359347    23          c.2309-2A\>G                        SPLICING            rs111729952     yes                                                                                                known/pathogenic               
  chr11      47359115    24          c.2429G\>A           Arg810His      MISSENSE            rs375675796     yes           0.00008 (T)   deleterious 0      probably damaging 1       deleterious −4.564        known/likely pathogenic        
  chr11      47359085    24          c.2459G\>A           Arg820Gln      MISSENSE            rs2856655       yes                         deleterious 0      probably damaging 0.98    deleterious −2.925        known/likely pathogenic        
  chr11      47356592    26          c.2905+1G\>A                        SPLICING            rs397515991     yes                                                                                                known/pathogenic               
  chr11      47355264    28          c.3034C\>T           Gln1012Ter     STOP                rs730880586     yes                                                                                                known/pathogenic               
  chr11      47354882    29          c.3192_3193insC      Lys1065Glnfs   INS                 rs397516007     yes                                                                                                known/pathogenic               
  chr11      47353801    32          c.3636T\>G           Ile1212Met     MISSENSE                                                        deleterious 0      probably damaging 0.918   deleterious −2.498        new/likely pathogenic          
  chr11      47353662    32          c.3775C\>T           Gln1259Ter     STOP                rs730880605     yes                                                                                                known/pathogenic               
  *MYH7*     chr14       23900850    8                    c.676G\>A      Ala226Thr           MISSENSE                                                       deleterious 0             probably damaging 0.985   neutral −1.757                 new/uncertain significance
  chr14      23896866    16          c.1816G\>A           Val606Met      MISSENSE            rs121913627     yes                                                                                                known/pathogenic               
  chr14      23896042    18          c.1988G\>A           Arg663His      MISSENSE            rs371898076     yes           0.00008 (T)                                                                          known/pathogenic               
  chr14      23895189    19          c.2146G\>C           Gly716Arg      MISSENSE            rs121913638     yes                         deleterious 0.01   probably damaging 0.995   deleterious −3.728        known/likely pathogenic        
  chr14      23895179    19          c.2156G\>A           Arg719Gln      MISSENSE            rs121913641     yes                                                                                                known/pathogenic               
  chr14      23894116    22          c.2543_2545 delAAG   Lys847del      DEL                                 yes                                                                                                known/pathogenic               
  chr14      23893234    23          c.2804A\>T           Glu935Val      MISSENSE            rs730880761     yes                                                                                                known/pathogenic               
  chr14      23891501    25          c.3133C\>T           Arg1045Cys     MISSENSE            rs45611033      yes           0.00020 (A)   deleterious 0.03   benign 0.203              deleterious −6.180        known/uncertain significance   
  chr14      23889413    27          c.3367G\>C           Glu1123Gln     MISSENSE                                                        deleterious 0.01   probably damaging 0.968   neutral −2.389            new/uncertain significance     
  chr14      23887615    30          c.3973G\>A           Ala1325Thr     MISSENSE/SPLICING                                               deleterious 0.02   possibly damaging 0.751   neutral −2.329            new/uncertain significance     
  *TNNT2*    chr1        201334751   9                    c.281G\>C      Arg94Thr            MISSENSE        rs397516452   yes                              deleterious 0             possibly damaging 0.573   deleterious −5.588             known/uncertain significance
  chr1       201330414   14          c.794A\>T            Lys265Ile      MISSENSE            rs397516482     yes                         deleterious 0      probably damaging 0.958   deleterious −6.86         known/uncertain significance   
  chr1       201328373   16          c.853C\>T            Arg285Cys      MISSENSE            rs121964857     yes                         tolerated 0.06     probably damaging 0.978   neutral −2.09             known/likely pathogenic        
  *MYH6*     chr14       23873951    7                    c.611G\>A      Arg204His           MISSENSE        rs200623022   yes                              tolerated 0.05            possibly damaging 0.807   neutral −1.327                 known/uncertain significance
  chr14      23865497    20          c.2425C\>T           Arg809Cys      MISSENSE                                                        deleterious 0      probably damaging 0.963   deleterious −5.294        new/likely pathogenic          
  chr14      23853697    36          c.5519A\>G           Lys1840Arg     MISSENSE            rs373629059                                 tolerated 0.13     probably damaging 0.999   neutral −1.731            known/uncertain significance   
  *MYL2*     chr12       111350901   6                    c.401A\>C      Glu134Ala           MISSENSE        rs143139258   yes                              deleterious 0.01          possibly damaging 0.755   Deleterious −5.696             known/likely pathogenic
  *MYL3*     chr3        46902303    3                    c.170C\>A      Ala57Asp            MISSENSE        rs139794067   yes                              deleterious 0             probably damaging 0.996   deleterious −5.236             known/uncertain significance
  *TNNI3*    chr19       55665561    6                    c.385C\>G      Thr128Ser           MISSENSE                                                       tolerated 0.186           benign 0.000              neutral 0.61                   new/likely benign
  chr19      55665516    6           c.431T\>A            Leu144Gln      MISSENSE            rs121917760     yes                                                                                                known/pathogenic               

Prev. Rep.: previously reported; GMAF: Global minor allele frequency; Software prediction programs used for sequence variant interpretation: SIFT: Evolutionary conservation; POLYPHEN: Protein structure/function and evolutionary conservation; PROVEAN: Alignment and measurement of similarity between variant sequence and protein sequence homolog.
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###### 

Mutations detected per patient.

  Early-Onset                                                                                                                                                                                                                                 
  ---------------- ----------------- -------------------- ----------- ------------------------------ ------------------------------ ------------------- ------------------------------ ------------- ------------------------- -------------- ---------------------
  EO1              yes               *MYBPC3*             5           c.553A\>T                      Lys185Ter                      STOP                known/pathogenic               rs375607980   yes                       384            202
  EO2              yes               *MYH7*               19          c.2156G\>A                     Arg719Gln                      MISSENSE            known/pathogenic               rs121913641   yes                       399            204
  EO3                                *CAV3*               2           c.233C\>T                      Thr78Met                       MISSENSE            known/uncertain significance   rs72546668    yes                       124            57
  EO4                                *MYBPC3*             23          c.2309-2A\>G                                                  SPLICING            known/pathogenic               rs111729952   yes                       400            186
  EO5                                *MYH7*               16          c.1816G\>A                     Val606Met                      MISSENSE            known/pathogenic               rs121913627   yes                       383            204
  EO6              yes               *MYH7*               8           c.676G\>A                      Ala226Thr                      MISSENSE            new/uncertain significance                                             399            208
  *GLA*            6                 c.937G\>T            Asp313Tyr   MISSENSE                       known/uncertain significance   rs28935490          yes                            399           183                                      
  EO7              yes               *MYBPC3*             28          c.3034C\>T                     Gln1012Ter                     STOP                known/pathogenic               rs730880586   yes                       397            194
  EO8              yes               *MYBPC3*             23          c.2309-2A\>G                                                  SPLICING            known/pathogenic               rs111729952   yes                       398            204
  EO9              yes               *MYH7*               19          c.2146G\>C                     Gly716Arg                      MISSENSE            known/likely pathogenic        rs121913638   yes                       354            169
  EO11             yes               *MYBPC3*             16          c.1483C\>T                     Arg495Trp                      MISSENSE            known/uncertain significance   rs397515905   yes                       400            259
  *CAV3*           2                 c.216C\>G            Cys72Trp    MISSENSE                       known/uncertain significance   rs116840776         yes                            400           182                                      
  EO12             yes               *MYBPC3*             23          c.2309-2A\>G                                                  SPLICING            known/pathogenic               rs111729952   yes                       399            185
  EO13                               *MYBPC3*             32          c.3636T\>G                     Ile1212Met                     MISSENSE            new/likely pathogenic                                                  400            201
  23               c.2309-2A\>G                           SPLICING    known/pathogenic               rs111729952                    yes                 399                            187                                                    
  16               c.1591G\>C        Gly531Arg            MISSENSE    known/likely pathogenic        rs397515912                    yes                 400                            184                                                    
  EO14                               *CAV3*               2           c.233C\>T                      Thr78Met                       MISSENSE            known/uncertain significance   rs72546668    yes                       399            214
  EO17                               *MYBPC3*             22          c.2308G\>A                     Asp770Asn                      MISSENSE/SPLICING   known/pathogenic               rs36211723    yes                       399            195
  EO18             yes               *MYBPC3*             13          c.1120C\>G                     Tyr374Ter                      STOP                known/pathogenic               rs730880635   yes                       400            225
  EO19             yes               *MYBPC3*             32          c.3775C\>T                     Gln1259Ter                     STOP                known/pathogenic               rs730880605   yes                       398            204
  EO20             yes               *MYL2*               6           c.401A\>C                      Glu134Ala                      MISSENSE            known/likely pathogenic        rs143139258   yes                       398            191
  EO21             yes               *MYBPC3*             5           c.565G\>A                      Val189Ile                      MISSENSE            known/uncertain significance   rs11570052    yes                       309            253
  *MYH7*           22                c.2543_2545 delAAG   Lys847del   DELETION                       known/pathogenic                                   yes                            391           194                                      
  EO22                               *CAV3*               2           c.400G\>T                      Ala134Ser                      MISSENSE            new/uncertain significance                                             330            168
  EO23                               *MYH7*               30          c.3973G\>A                     Ala1325Thr                     MISSENSE/SPLICING   new/uncertain significance                                             400            176
  23               c.2804A\>T        Glu935Val            MISSENSE    known/pathogenic               rs730880761                    yes                 400                            206                                                    
  EO25             yes               *MYBPC3*             15          c.1409G\>A                     Arg470Gln                      MISSENSE            known/uncertain significance                 yes                       293            130
  EO26             yes               *TNNT2*              16          c.853C\>T                      Arg285Cys                      MISSENSE            known/likely pathogenic        rs121964857   yes                       323            167
  EO27             yes               *TNNT2*              14          c.794A\>T                      Lys265Ile                      MISSENSE            known/uncertain significance   rs397516482   yes                       395            193
  EO29             yes               *MYBPC3*             24          c.2429G\>A                     Arg810His                      MISSENSE            known/likely pathogenic        rs375675796   yes                       400            148
  EO30             yes               *TNNI3*              6           c.431T\>A                      Leu144Gln                      MISSENSE            known/pathogenic               rs121917760   yes                       398            227
  EO31                               *MYBPC3*             5           c.565G\>A                      Val189Ile                      MISSENSE            known/likely benign            rs11570052    yes                       312            152
  EO32                               *MYH7*               18          c.1988G\>A                     Arg663His                      MISSENSE            known/pathogenic               rs371898076   yes                       400            211
  EO33                               *MYBPC3*             29          c.3193_3194 insC               Lys1065Glnfs                   INSERTION           known/pathogenic               rs397516007   yes                       398            194
  16               c.1591G\>C        Gly531Arg            MISSENSE    known/likely pathogenic        rs397515912                    yes                 400                            212                                                    
  13               c.1112C\>G        Pro371Arg            MISSENSE    known/uncertain significance   rs397515887                    yes                 235                            87                                                     
  EO34             yes               *TNNT2*              9           c.281G\>C                      Arg94Thr                       MISSENSE            known/uncertain significance   rs397516452   yes                       400            196
  EO35                               *MYBPC3*             26          c.2905+1G\>A                   ex26                           SPLICING            known/pathogenic               rs397515991   Yes                       296            139
  **Late-Onset**                                                                                                                                                                                                                              
  **Patient ID**   **Familiarity**   **Gene ID**          **Exon**    **DNA Change**                 **Protein Change**             **Mutation Type**   **Clinical Significance**      **dbSNP**     **Previously Reported**   **Coverage**   **Allele Coverage**
  LO1              Yes               *MYH7*               25          c.3133C\>T                     Arg1045Cys                     MISSENSE            known/uncertain significance   rs45611033    yes                       213            113
  LO4                                *MYH7*               27          c.3367G\>C                     Glu1123Gln                     MISSENSE            new/uncertain significance                                             400            220
  LO6                                *MYH6*               20          c.2425C\>T                     Arg809Cys                      MISSENSE            new/ likely pathogenic                                                 299            139
  LO8              Yes               *MYBPC3*             16          c.1624G\>C                     Glu542Gln                      MISSENSE/SPLICING   known/pathogenic               rs121909374   yes                       353            188
  *TNNI3*          6                 c.385C\>G            Thr128Ser   MISSENSE                       new/likely benign                                                                 400           204                                      
  LO13             Yes               *MYH7*               16          c.1816G\>A                     Val606Met                      MISSENSE            known/pathogenic               rs121913627   yes                       383            204
  LO14                               *MYH6*               36          c.5519A\>G                     Lys1840Arg                     MISSENSE            known/uncertain significance   rs373629059   yes                       399            196
  LO16                               *MYBPC3*             24          c.2459G\>A                     Arg820Gln                      MISSENSE            known/likely pathogenic        rs2856655     yes                       400            213
  LO17                               *MYH6*               7           c.611G\>A                      Arg204His                      MISSENSE            known/uncertain significance   rs200623022   yes                       398            201
  *MYL3*           3                 c.170C\>A            Ala57Asp    MISSENSE                       known/uncertain significance   rs139794067         yes                            398           168                                      

dbSNP: database single nucleotide polymorphisms ([www.ncbi.nlm.nih.gov/SNP](www.ncbi.nlm.nih.gov/SNP)).
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